Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects
Top Cited Papers
- 21 September 2015
- journal article
- review article
- Published by Hindawi Limited in Human Mutation
- Vol. 36 (12), 1113-1127
- https://doi.org/10.1002/humu.22904
Abstract
Pulmonary arterial hypertension (PAH) is an often fatal disorder resulting from several causes including heterogeneous genetic defects. While mutations in the bone morphogenetic protein receptor type II (BMPR2) gene are the single most common causal factor for hereditary cases, pathogenic mutations have been observed in approximately 25% of idiopathic PAH patients without a prior family history of disease. Additional defects of the transforming growth factor beta pathway have been implicated in disease pathogenesis. Specifically, studies have confirmed activin A receptor type II‐like 1 (ACVRL1), endoglin (ENG), and members of the SMAD family as contributing to PAH both with and without associated clinical phenotypes. Most recently, next‐generation sequencing has identified novel, rare genetic variation implicated in the PAH disease spectrum. Of importance, several identified genetic factors converge on related pathways and provide significant insight into the development, maintenance, and pathogenetic transformation of the pulmonary vascular bed. Together, these analyses represent the largest comprehensive compilation of BMPR2 and associated genetic risk factors for PAH, comprising known and novel variation. Additionally, with the inclusion of an allelic series of locus‐specific variation in BMPR2, these data provide a key resource in data interpretation and development of contemporary therapeutic and diagnostic tools.Keywords
This publication has 101 references indexed in Scilit:
- BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary HypertensionLung, 2014
- Pre-implantation genetic diagnosis in pulmonary arterial hypertension due toBMPR2mutation: Figure 1–European Respiratory Journal, 2012
- Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutationsRespiratory Research, 2011
- Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PHInternational Journal of Clinical Practice, 2011
- Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patientsJournal of Medical Genetics, 2011
- Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) MutationAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 MutationAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Caveolae and endothelial dysfunction: Filling the caves in cardiovascular diseaseEuropean Journal of Pharmacology, 2008
- Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth MuscleCirculation Research, 2004
- Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout miceProceedings of the National Academy of Sciences of the United States of America, 2002